1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsNIH HEAL Initiative: Integrative Management of chronic Pain and OUD for Whole Recovery (IMPOWR) - Building Engagement, Assistance, Capacity, Outreach, and Networks (BEACON) Center is sponsored by National Institute on Drug Abuse (NIDA). This opportunity supports mission-aligned projects and measurable outcomes.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Opportunity Listing - HEAL Initiative: Integrative Management of chronic Pain and OUD for Whole Recovery (IMPOWR) - Building Engagement, Assistance, Capacity, Outreach, and Networks (BEACON) Center HEAL Initiative: Integrative Management of chronic Pain and OUD for Whole Recovery (IMPOWR) - Building Engagement, Assistance, Capacity, Outreach, and Networks (BEACON) Center Agency: National Institutes of Health Assistance Listings: 93.
279 -- Drug Use and Addiction Research Programs Last Updated: January 8, 2026 View version history on Grants. gov 40-75% percent of individuals with opioid use disorder (OUD) have co-occurring chronic pain (CP), which impacts their ability to fully engage in treatment. Effective management of both conditions is hindered by siloed medical disciplines and health systems.
HEAL Integrative Management of Chronic Pain and OUD for Whole Recovery (IMPOWR) was funded in FY21 to test novel interventions for the management of co-occurring CP and OUD at the patient level. This initiative will test different implementation strategies and other approaches to address scalability and sustainability of evidence based practices for CP and OUD from a health system perspective.
Studies will engage key decision leaders in health systems including but not limited to: peer specialists, clinicians, health system leaders, and payers. Studies will execute a single hybrid II/III implementation-effectiveness trial to focus on collaborative care models and implementation strategies to meaningfully integrate CP and OUD service provision in diverse health settings.
These studies will address complex factors that influence the ability to scale and sustain effective and integrated care for CP and OUD.
The BEACON Center will provide: (1) network coordination support, (2) capacity building at the intersection of CP, OUD, and implementation science, (3) annual surveys/qualitative activities to understand different barriers and attitudes impacting access and sustained use to integrated CP and OUD service delivery, (4) develop important resources for key stakeholder audiences that can inform/improve sustainability and scalability of evidence-based practices.
The National Institute on Drug Abuse (NIDA) in partnership with National Institute on Alcohol and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Mental Health (NIMH), and National Center for Complementary and Integrative Health (NCCIH), and National Institute of Neurological Disorders and Stroke (NINDS) intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications for research on the effective management of OUD and CP.
Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. This NOFO will utilize the U2C activity code.
Investigators with expertise and insights into this area of CP management and OUD/opioid misuse are encouraged to begin to consider applying for this new NOFO.
In addition, collaborative investigations combining expertise in community-based participatory research approaches, implementation science, and other strategies to amplify scalability and sustainability will be encouraged and, these investigators should also begin considering applying for this NOFO. Grant authorities that allow NIDA to forecast this opportunity are as follows: 42 U.S.C. § 241 and § 284.
Other Native American tribal organizations Nonprofits non-higher education with 501(c)(3) Nonprofits non-higher education without 501(c)(3) For-profit organizations other than small businesses Independent school districts Private institutions of higher education Public and state institutions of higher education City or township governments Special district governments Federally recognized Native American tribal governments Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
Grantor contact information No documents are currently available. Link to additional information Estimated Application Due Date : Estimated Due Date Description : Estimated Project Start Date : Funding opportunity number : Cost sharing or matching requirement : Funding instrument type : Opportunity Category Explanation : Category of Funding Activity :
According to the current listing, eligibility includes: Researchers and institutions focused on integrated chronic pain and OUD management. Confirm the full requirements in the official notice before applying.
NIH HEAL Initiative: Integrative Management of chronic Pain and OUD for Whole Recovery (IMPOWR) - Building Engagement, Assistance, Capacity, Outreach, and Networks (BEACON) Center is funded by National Institute on Drug Abuse (NIDA). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
The HEAL Initiative's Studies to Enable Analgesic Discovery award (RFA-NS-25-023) puts federal money exactly where private capital won't go — the assay-building, screening, and hit-characterization stage of non-opioid pain therapeutics. It's a phased R61/R33, up to $350,000 in direct costs per year, with the next application deadline September 17, 2026. Here is how the two-phase structure works, who's eligible, and how to build a proposal that survives the R61-to-R33 milestone gate.
Read articleARPA-H's FASTPASS program targets a public-health blind spot: substandard and contaminated drugs that are only caught after patients are exposed. It funds through-package chemical sensing (TA1 SAMPLE) and the analytics to act on it (TA2 DETECT). The solicitation posts to SAM.gov in mid-August 2026, with a virtual Proposer Workshop on August 24 and registration closing August 20. Here is what FASTPASS funds, why the timing matters, and how to position a cross-disciplinary team.
Read articleARPA-H PROSPR program funds seven research teams testing rapamycin, semaglutide, and novel compounds to extend healthspan. A deep analysis of the science, the money, and what it means for the field.
Read article